Skip to main content
SpringerLink
Log in

Hypnotics

Drug Selection by Means of the System of Objectified Judgement Analysis (SOJA) Method

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

Selection of hypnotics for drug formularies in The Netherlands, France and the UK is made by means of the System of Objectified Judgement Analysis (SOJA) method. The following criteria are included in the method: clinical efficacy (maximal 300 points), adverse effects (250 points), clinical documentation (150 points), cost (120 points), pharmacokinetic properties (80 points), toxicity (50 points), drug interactions (30 points) and the number oftablet strengths available (20 points).

In all 3 countries, zolpidem, zopiclone and temazepam showed the highest score, followed by lormetazepam. High scores favour inclusion in formularies. Nitrazepam and loprazolam scored 75 to 130 points less than the top 3, and flunitrazepam shows the lowest score (119 to 183 points less than zolpidem, zopiclone and temazepam). Therefore, the first 3 (or 4) hypnotics are most suitable for formulary inclusion while the others are not.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Springer MP, Eykelenboom PR. Slaapstoornissen, diagnostiek en behandeling door de huisarts. DIMS (Dutch publication of the International of Medical Statistics) 1989; nr8: 4–11

    Google Scholar 

  2. Zitman FG. De behandeling van slaapstoornissen met benzodiazepines DIMS (Dutch publication of the International of Medical Statistics) 1989; nr 8: 12–17

    Google Scholar 

  3. Breemhaar E, Kroesbergen HT, Damen F. Medicijgebruik van ouderen in het land van Heusden en Altena. 1993 GGD Stadsgewest Breda IVA Instituut voor Sociaal Wetenschappelijk Onderzoek Til burg

  4. Danhof M, Breimcr DD. Farmacokinetische keuzecriteria van slaapmiddelen. Tijdschr Geneesm Onderz/J Drug Research 1985; 10: 889–894

    Google Scholar 

  5. Moleman P. Farmacologische keuzecriteria voor slaapmiddelen. Tijdschr Geneesm Onderz/J Drug Research 1985; 10: 877–881

    Google Scholar 

  6. Hoes MJAJM. NlKlinische keuzecriteria van slaapmiddelen. Tijdschr Geneesm Onderz/J Drug Research 1985; 10: 882–888

    Google Scholar 

  7. Van der Kleijn E, Zuidgeest T, Groen M, et al. Keuzecriteria en net gebniik van slaapmiddelen. Tijdschr Geneesm Onderz/J Drug Research 1985; 10: 859–864

    Google Scholar 

  8. Oswald I. Criteria for selecting an hypnotic. Tijdschr Geneesm Onderz/J Drug Research 1984; 9: 480–486

    Google Scholar 

  9. Dingemanse J. Pharmacotherapy of insomnia: practice and prospects. Pharm World Sci 1995; 17: 67–75

    Article  PubMed  CAS  Google Scholar 

  10. Steenhoek A, Janknegt R, Oldenhof HGJ, et al. SOJA systeem: hulp bij belangrijke keuzemomenten in de farmacie. Pharm Weekbl 1988; 123: 75–79

    Google Scholar 

  11. Janknegt R. Fluoroquinolones: use of clinical data to aid formulary choice by the System of Objective Judgement Analysis (SOJA) method. PharmacoEconomics 1994; 6: 15–33

    Article  PubMed  CAS  Google Scholar 

  12. Jochemsen R, van Boxtel CJ, Hermans J, et al. Kinetics of five benzodiazepine hypnotics in healthy subjects. Clin Pharmacol Ther 1983; 3–4: 42–47

    Article  Google Scholar 

  13. Crevoisier C, Ziegler WH, Eckert M, et al. Relationship between plasma concentration and effect of midazolam after oral and intravenous administration. Br J Clin Pharmacol 1983; 16: 51S–61S

    Article  PubMed  Google Scholar 

  14. Morgan K. Hypnotics in the elderly: what cause for concern? Drugs 1990; 40: 688–696

    Article  PubMed  CAS  Google Scholar 

  15. Garzone PD, Kroboth PD. Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1989; 16: 337–364

    Article  PubMed  CAS  Google Scholar 

  16. Doenicke A. Klinisch-pharmakologische Aspekte. In: Hergmann H, ed. Benzodiazepine-klinische Bedeutung und Anwendung. Maudrich: Vienna, 1987: 39–59

    Google Scholar 

  17. Wadworth AN, McTavish D. Zopiclone: a review of its pharmacological properties and therapeutic efficacy as an hypnotic. Drugs Aging 1993; 3: 441–459

    Article  PubMed  CAS  Google Scholar 

  18. Jochemsen R, van Rijn PA, Hazelzet TGM. Assay of midazolam, brotizolam and loprazolam in plasma by a gas chromatography and a radioreceptor technique. In: Jochemsen R. Clinical pharmacokinetics of benzodiazepine hypnotics [thesis]. Leiden: Univ. of Leiden, 1983: 66–77

    Google Scholar 

  19. Jochemsen R, Hogendoom JJH, Dingemanse J, et al. Pharmacokinetics and bioavailability of intravenous, oral and rectal nitrazepam in humans. In: Jochemsen R. Clinical pharmacokinetics of benzodiazepine hypnotics [thesis]. Leiden: Univ. of Leiden, 1983: 97–111

    Google Scholar 

  20. Langtry HD, Benfield P. Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990; 40: 291–313

    Article  PubMed  CAS  Google Scholar 

  21. Jochemsen R, van Rijn PA, Hazelzet TGM, et al. Comparative pharmacokinetics of midazolam and loprazolam in healthy subjects after oral administration. In: Jochemsen R. Clinical phamacokinetics of benzodiazepine hypnotics [thesis]. Leiden: Univ. of Leiden, 1983: 176–183

    Google Scholar 

  22. Knuistingh-Neven A, de Graaf WJ, Lucassen PLEJ, et al. NHG-standaard Slapeloosheid en slaapmiddelen. Huisarts Wet 1992; 35: 212–219

    Google Scholar 

  23. Greenblatt DJ. Clinical implications of pharmacokinetic differences among benzodiazepines. Act Med Int Psychiatrie 1985; 2 Suppl. 1: 8–12

    Google Scholar 

  24. Jochemsen R, Breimer DD. Pharmacokinetics of benzodiazepine hypnotics in man. Pharm Int 1984; 5: 244–248

    CAS  Google Scholar 

  25. Declerck AC. Wauqier A. Slaapstoornissen. Weert: M & P, 1986: 126–129

    Google Scholar 

  26. van Dongen PAM. Waken en slapen. Tilburg: Janssen Pharmaceutica, 1991

    Google Scholar 

  27. Goldenberg F. Implications of changes in sleep architecture induced by hypnotics. JAMA (South East Asian version) 1993 Suppl. 9: 8–12

    Google Scholar 

  28. Greenblatt DJ. Clinical applications of pharmacokinetic differences among benzodiazepines. In: Hoes MJAJM, Broers M. Patay M, editors. Clinical differentation of benzodiazepines. 1986: 11–19

    Google Scholar 

  29. O’Hanlon JF. Benzodiazepine influence on driving proficiency. In: Hoes MJAJM. Broers M, Patay M. editors. Clinical differentiation of benzodiazepines. 1986: 31–36

    Google Scholar 

  30. Loonen AJM. Benzodiazepines; een dankbaar gespreksonderwerp. Pharm Weekbl 1986; 121: 420–428

    CAS  Google Scholar 

  31. Van der Laan JW. Afhankelijkheid van benzodiazepines, omvang, risico’s en eventuele verschillen tussen de middelen onderling. Ned Tijdschr Geneeskd 1984; 128: 809–814

    Google Scholar 

  32. Owen RT, Tyrer P. Benzodiazepine dependence: a review of the evidence. Drugs 1983; 25: 385–398

    Article  PubMed  CAS  Google Scholar 

  33. Ashton H. Benzodiazepine withdrawal: an unfinished story. BMJ 1984; 288: 1135–1140

    Article  PubMed  CAS  Google Scholar 

  34. Greenblatt DJ. Shader RJ, Abernethy DR. Current status of benzodiazepines. N Engl J Med 1985; 309 (2 Pt 2): 410–416

    Google Scholar 

  35. Sepphia T, Nuotto F, Dreyfuss JF. Drug alcohol interaction on psychomotor skills: zopiclone and flunitrazepam. Pharmacology 1983; 27 Suppl. 2: 127–135

    Article  Google Scholar 

  36. Olkkola KT. Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53: 298–305

    Article  PubMed  CAS  Google Scholar 

  37. Green DS, Dockens RC, Salazar DE. Coadministration of nefazodone and benzodiazepines: I. Pharmacokinetic assessment. Clin Pharmacol Ther 1994; 55: 141

    Google Scholar 

  38. Hindmarch I. Assesment of daytime psychomotor performance and memory effects of hypnotic drugs. JAMA (South East Asian edition) 1993: 9 Suppl.: 13–16

    Google Scholar 

  39. Informatorium Medicamentorum 1996. The Hague, the Netherlands: Ro← Dutch Societs of Pharmacv 199b

  40. Allain N. Delahaye C, Le Cox F. et al. Postmarketing surveillance of zopiclone in insomnia: analysis of 20,513 cases. Sleep 1991; 14: 408–413

    PubMed  CAS  Google Scholar 

  41. King DJ. Benzodiazepines, amnesia and sedation: theoretical and clinical issues and controversies. Hum Psychopharmac 1992; 7: 79–87

    Article  Google Scholar 

  42. Subhan Z, Hindmarch I. Effect of zopiclone and benzodiazepine hypnotics on search in short-term memory. Neuropsychobiology 1984; 12: 244–248

    Article  PubMed  CAS  Google Scholar 

  43. Fossen A, Goddibsen OB, Loyning Y, Dreyfus JF. Effects of hypnotics on memory. Pharmacol 1983; 17 Suppl. 2: 116–126

    Article  Google Scholar 

  44. Rotenberg VS. Sleep and memory: I. The influence of different sleep stages on memory. Neurosci Biobehav Rev 1992; 16: 497–502

    Article  PubMed  CAS  Google Scholar 

  45. Rotenberg VS. Sleep and memory: II. Investigations on humans. Neurosci Biobehav Rev 1992; 16: 503–505

    Article  PubMed  CAS  Google Scholar 

  46. Bixler EO, Kales A, Brubaker BH, et al. Adverse reactions to benzodiazepine hypnotics: spontaneous reporting svstem. Pharmacology 1987; 35: 286–300

    Article  PubMed  CAS  Google Scholar 

  47. Schou J. Triazolam: adverse effects in relation to dosage. Pharmacol Toxicol 1989; 64: 6–8

    Article  PubMed  CAS  Google Scholar 

  48. Marks J. Techniques of benzodiazepine withdrawal in clinical practice. Med Toxicol 1988; 3: 324–333

    CAS  Google Scholar 

  49. Smith DE. Benzodiazepine dependence potential: current studies and trends. J Subst Abuse Treat 1984; 1: 163–167

    Article  PubMed  CAS  Google Scholar 

  50. Fleischhacker WW, Barnas C, Hackenberg B. Epidemiology of benzodiazepine dependence. Acta Psychiatr Scand 1986; 74: 80–83

    Article  PubMed  CAS  Google Scholar 

  51. Marks J. Benzodiazepine dependence in perspective. In: Nicholson AN. ed. Hypnotics in clinical practice. Oxford: Medicine Publishing Foundation, 1982: 67–73

    Google Scholar 

  52. Kazamatsuri H. A clinical study on dependence liability of zopiclone [abstract]. 4th International Congress on Sleep Research: 1983; Bologne

    Google Scholar 

  53. Boisal K, Dreyfus JF, Delmotte M. Studies on the dependence-inducing potential of zopiclone and triazolam. Pharmacology 1983; 27 Suppl. 2: 242–247

    Article  Google Scholar 

  54. Bixler EO, Kales JD, Kales A, et al. Rebound insomnia and elimination half-life: assessment of individual subject response. J Clin Pharmacol 1985; 25: 115–124

    PubMed  CAS  Google Scholar 

  55. Gullin JC, Spinweber CL, Johnson LC. Rebound insomnia: a critical review. J Clin Psychopharmacol 1989; 9: 161–172

    Google Scholar 

  56. Roehrs T, Volgel G, Roth T. Rebound insomnia: its determinants and significance. Am J Med 1990; 88 Suppl. 3A: 39–42

    Google Scholar 

  57. Van Dam JG. Slaapmiddelen en rebound-slapeloosheid: benzodiazepinen en zopiclon. Pharm Weekbl 1991; 126: 116–117

    Google Scholar 

  58. Kornaat H. Slaapmiddelen en rebound-slapeloosheid: benzodiazepines en zopiclon II (ingezonden brief). Pharm Weekbl 1991; 126: 555–556

    Google Scholar 

  59. Kamphuisen HAC, van Dijk JG. Snurken en het slaapapnoe syndroom. Practitioner 1988; 5: 785–787

    Google Scholar 

  60. Phillipson EA. Sleep apnoea: a major public health problem. N Engl J Med 1993; 328: 1271–1273

    Article  PubMed  CAS  Google Scholar 

  61. Hoes MJAJM. Over slaapmiddelen: de plaats van Zopiclone. Tijdschr Geneesm Onderz/J Drug Research 1993; 18: 90–94

    Google Scholar 

  62. Ranlov PJ, Nielsen SP. Effect of zopiclone and diazepam on ventilatory response in normal human subjects. Sleep 1987; 10 Suppl.: 40–47

    PubMed  Google Scholar 

  63. Van Heijst ANP, Pikaar SA, editors. Vergiftigingen. Utrecht: Scheltemaen Holkema, 1988

  64. Nicholson AN. Hypnotics: their place in therapeutics. Drugs 1988; 31: 164–176

    Article  Google Scholar 

  65. Beckmann H, Haas S. Therapie mit benzodiazepines eine Bilanz. Nervenarzt 1984; 55: 111–121

    PubMed  CAS  Google Scholar 

  66. Langley MS, Clissold SP. Brotizolam: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 1988; 35: 104–122

    Article  PubMed  CAS  Google Scholar 

  67. Clark BG, Jue SG. Dawson GW. et al. Loprazolam: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in insomnia. Drugs 1986; 31: 500–516

    Article  PubMed  CAS  Google Scholar 

  68. Dundee JW, Halliday NJ. Harper KW. et al. Midazolam: a review of its pharmacological properties and therapeutic use. Drugs 1984; 28: 519–543

    Article  PubMed  CAS  Google Scholar 

  69. Pakes GE. Brogden RN. Heal RC. et al. Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia. Drugs 1981: 22: 91–110

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy and Toxicology, Maasland Ziekenhuis, P.O. Box 5500, 6130 MB, Sittard, The Netherlands

    Robert Janknegt

  2. Pharmacist, Loon op Zand, The Netherlands

    Ary van der Kuy

  3. Kempenhaeghe, Heeze, The Netherlands

    Guus Declerck

  4. Springfield Brookmount, Lisbum, Co. Antrim, Northern Ireland

    Chris Idzikowski

Authors
  1. Robert Janknegt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ary van der Kuy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guus Declerck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chris Idzikowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Janknegt, R., van der Kuy, A., Declerck, G. et al. Hypnotics. Pharmacoeconomics 10, 152–163 (1996). https://doi.org/10.2165/00019053-199610020-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199610020-00007

Keywords

Search

Navigation